BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAD3. A total of 5 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $3,721,000 | -85.3% | 982,000 | -84.4% | 0.70% | -76.7% |
| Q1 2016 | $25,334,000 | -36.5% | 6,304,000 | -19.2% | 3.00% | +7.3% |
| Q4 2015 | $39,903,000 | -2.3% | 7,804,000 | -2.4% | 2.80% | +43.2% |
| Q3 2015 | $40,855,000 | -24.2% | 8,000,000 | 0.0% | 1.95% | -0.4% |
| Q2 2015 | $53,880,000 | +9.7% | 8,000,000 | 0.0% | 1.96% | +11.2% |
| Q1 2015 | $49,130,000 | +37.5% | 8,000,000 | 0.0% | 1.76% | +9.8% |
| Q4 2014 | $35,720,000 | +25.2% | 8,000,000 | 0.0% | 1.61% | +69.6% |
| Q3 2014 | $28,540,000 | +16.0% | 8,000,000 | 0.0% | 0.95% | +22.0% |
| Q2 2014 | $24,605,000 | -8.7% | 8,000,000 | 0.0% | 0.78% | -12.1% |
| Q1 2014 | $26,955,000 | -3.2% | 8,000,000 | 0.0% | 0.88% | +0.7% |
| Q4 2013 | $27,840,000 | -3.2% | 8,000,000 | 0.0% | 0.88% | -15.6% |
| Q3 2013 | $28,760,000 | +29.6% | 8,000,000 | 0.0% | 1.04% | +28.2% |
| Q2 2013 | $22,185,000 | – | 8,000,000 | – | 0.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GLG Partners LP | 18,250,000 | $50,831,000 | 1.94% |
| MACKAY SHIELDS LLC | 9,117,000 | $25,277,000 | 1.35% |
| Baker Brothers Advisors | 22,898,000 | $63,217,000 | 1.25% |
| Amici Capital, LLC | 8,000,000 | $22,185,000 | 0.81% |
| Verition Fund Management LLC | 1,075,000 | $2,981,000 | 0.55% |
| Pine River Capital Management L.P. | 4,700,000 | $13,089,000 | 0.19% |
| PALISADE CAPITAL MANAGEMENT, LP | 2,000,000 | $5,570,000 | 0.16% |
| SYMPHONY ASSET MANAGEMENT LLC | 324,000 | $898,000 | 0.09% |
| AVIVA PLC | 2,000,000 | $5,615,000 | 0.06% |
| Cheyne Capital Management (UK) LLP | 2,000,000 | $74,000 | 0.05% |